Breast cancer could be detected up to five years before there are any clinical signs of it, using a blood test that identifies the body’s immune response to substances produced by tumour cells, according to new research presented at the 2019 NCRI Cancer Conference today (Sunday).
Cancer cells produce proteins called antigens that trigger the body to make antibodies against them – autoantibodies. Researchers at the University of Nottingham (UK) have found that these tumour-associated antigens (TAAs) are good indicators of cancer, and now they have developed panels of TAAs that are known already to be associated with breast cancer to detect whether or not there are autoantibodies against them in blood samples taken from patients.
In a pilot study the researchers, who are part of the Centre of Excellence for Autoimmunity in Cancer (CEAC) group at the School of Medicine, University of Nottingham, took blood samples from 90 breast cancer patients at the time they were diagnosed with breast cancer and matched them with samples taken from 90 patients without breast cancer (the control group).
They used screening technology (protein microarray) that allowed them to screen the blood samples rapidly for the presence of autoantibodies against 40 TAAs associated with breast cancer, and also 27 TAAs that were not known to be linked with the disease.
Presenting the research at the NCRI Conference, Ms Daniyah Alfattani, a PhD student in the group, said: “The results of our study showed that breast cancer does induce autoantibodies against panels of specific tumour-associated antigens. We were able to detect cancer with reasonable accuracy by identifying these autoantibodies in the blood.”
The researchers identified three panels of TAAs against which to test for autoantibodies. The accuracy of the test improved in the panels that contained more TAAs. The panel of five TAAs correctly detected breast cancer in 29% of the samples from the cancer patients and correctly identified 84% of the control samples as being cancer-free. The panel of seven TAAs correctly identified cancer in 35% of cancer samples and no cancer in 79% of control samples. The panel of nine antigens correctly identified cancer in 37% of cancer samples and no cancer in 79% of the controls.
“We need to develop and further validate this test,” said Ms Alfattani. “However, these results are encouraging and indicate that it’s possible to detect a signal for early breast cancer. Once we have improved the accuracy of the test, then it opens the possibility of using a simple blood test to improve early detection of the disease.”
The researchers are now testing samples from 800 patients against a panel of nine TAAs, and they expect the accuracy of the test to improve with these larger numbers.
“A blood test for early breast cancer detection would be cost effective, which would be of particular value in low and middle income countries. It would also be an easier screening method to implement compared to current methods, such as mammography,” said Ms Alfattani.
The researchers estimate that, with a fully-funded development programme, the test might become available in the clinic in about four to five years.
A similar test for lung cancer is currently being tested in a randomised controlled trial in Scotland, involving 12,000 people at high risk of developing lung cancer because they smoke. They have been randomised to have (or not) an autoantibody blood test called ELISA (Early CDT-Lung). Participants who test positive for the autoantibodies are then followed up with a CT scan every two years in order to detect lung cancer in its early stages when it is easier to treat.
The CEAC group is also working on similar tests for pancreatic, colorectal and liver cancers. Solid tumours like these, as well as lung and breast cancer, represent around 70% of all cancers.
“A blood test capable of detecting any of these cancers at an early stage is the over-riding objective of our work,” concluded Ms Alfattani.
Dr Iain Frame, CEO of NCRI said: “Early diagnosis using simple, non-invasive ways of detecting the first signs of cancer is a key strategic priority for NCRI and something we’d all like to see working in practice. The results from this pilot study for a blood test to detect early breast cancer are promising and build on this research group’s expertise in other cancers, such as lung cancer. It’s obviously early days but we look forward to seeing the results from the larger group of patients that are now being investigated.”
The Latest on: Breast cancer
via Google News
The Latest on: Breast cancer
- miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYBon December 11, 2019 at 2:16 am
Resistance to tamoxifen is a major clinical challenge. Research in recent years has identified epigenetic changes as mediated by dysregulated miRNAs that can possibly play a role in resistance to ...
- Breast Cancer Treatment & Therapeutics Market Global Analysis by Latest Innovation, Current Trend, Future Scope, Industry Size, Share by 2023on December 10, 2019 at 10:33 pm
Dec 11, 2019 (Heraldkeepers) -- The Report for Global Breast Cancer Market of Market Research Future Comprises of Extensive Primary Research Along with the Detailed Analysis of Qualitative as well as ...
- Breast Cancer Therapeutics Market Increase CAGR by Top International Players as Astra Zeneca, Pfizer Inc., Sanofi & more Forecast till 2025on December 10, 2019 at 8:36 pm
Dec 11, 2019 (The Expresswire) -- Breast Cancer Therapeutics Market to Grow Tremendous CAGR by 2026 Profiling Top Key Players are Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene ...
- Eisai to Present New Data on HALAVEN® (eribulin mesylate) Injection at 42nd Annual San Antonio Breast Cancer Symposiumon December 10, 2019 at 11:44 am
WOODCLIFF LAKE, N.J., Dec. 10, 2019 /PRNewswire/ -- Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (marketed as HALAVEN ®) ...
- Combination regimen shows promising results in preclinical models of triple negative breast canceron December 10, 2019 at 10:20 am
Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care ...
- Selective Effects of Thioridazine on Self-Renewal of Basal-Like Breast Cancer Cellson December 10, 2019 at 2:10 am
Several recent publications demonstrated that DRD2-targeting antipsychotics such as thioridazine induce proliferation arrest and apoptosis in diverse cancer cell types including those derived from ...
- Potential therapy discovered for deadly breast cancer that has few treatment optionson December 9, 2019 at 8:04 am
Mount Sinai researchers have designed an innovative experimental therapy that may be able to stop the growth of triple-negative breast cancer, the deadliest type of breast cancer, which has few ...
- New test predicts chance of living more than a year on targeted breast cancer treatmenton December 9, 2019 at 6:03 am
A new test could pick out women with advanced breast cancer who are likely to benefit from an exciting new targeted therapy for more than a year. Analysing levels of a molecule called cyclin E1 in ...
- Study shows safety of palbociclib for advanced breast cancer patients with unique gene alterationon December 9, 2019 at 5:17 am
Women who receive palbociclib (Ibrance ®) to treat their advanced breast cancer and have a gene alteration that can lead to a condition known as benign ethnic neutropenia (BEN), can safely receive the ...
- Nell Gifford, owner of Giffords Circus, dies of breast canceron December 9, 2019 at 1:49 am
Despite her illness, co-founder appeared in shows over the summer before her death at 46 ...
via Bing News